Even though compactin worked well in people, the company stopped developing it because dogs given very high doses got cancer.
Claim Context
The development of compactin was discontinued by Sankyo despite positive Phase II trial results in patients with severe hypercholesterolemia due to the observation of lymphoma in dogs at very high doses, highlighting the role of preclinical toxicity findings in halting drug development even in the presence of human efficacy signals.
“However, after the trial was completed, Sankyo halted work on the drug based on the observation that high doses of compactin were associated with development of lymphomas in dogs, even though these very high doses were unlikely ever to be used clinically.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Can summarize the historical context and rationale behind corporate drug development decisions.
A review article citing internal Sankyo reports, regulatory documents, and interviews with former researchers involved in the compactin program.
Could document the specific toxicological findings in dogs treated with high-dose compactin.
A 1980s-era case report from Sankyo’s preclinical lab describing 10 beagle dogs given 100 mg/kg/day compactin for 12 months, reporting incidence of lymphoma, liver histology, and survival.